Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Cannabidiol for Tobacco Cessation
NCT05445804Phase 1Recruiting
- Sponsor
- Johns Hopkins University
- Start
- Nov 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cannabidiol in Tobacco Use Disorder (TUD) (2 arms), sponsored by Johns Hopkins University. Primary endpoint: Biochemically-verified tobacco abstinence as assessed by expired carbon monoxide at 4 days. Started Nov 2022; status: recruiting.
02
Drugs
cannabidiol
03
Conditions
Tobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT05445804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05445804.